Larimar Therapeutics, Inc. (LRMR) stock
LRMRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.99−0.01 (-0.33%)
Close on Nov 17, 2026Market cap $310.61MP/E –Yield –
Larimar Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Larimar Therapeutics's operating cash flow for the twelve months ending Jun 30, 2025 was -$92.28M. For fiscal 2025 it was -$113.20M. The highest annual figure on record is -$13.59M in fiscal 2012.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$113.20M | – |
| FY2024 | Dec 31, 2024 | -$70.76M | – |
| FY2023 | Dec 31, 2023 | -$33.46M | – |
| FY2022 | Dec 31, 2022 | -$27.57M | – |
| FY2021 | Dec 31, 2021 | -$42.11M | – |
| FY2020 | Dec 31, 2020 | -$42.20M | – |
| FY2019 | Dec 31, 2019 | -$22.70M | – |
| FY2018 | Dec 31, 2018 | -$51.49M | – |
| FY2017 | Dec 31, 2017 | -$43.78M | – |
| FY2016 | Dec 31, 2016 | -$51.98M | – |
| FY2015 | Dec 31, 2015 | -$59.55M | – |
| FY2014 | Dec 31, 2014 | -$28.24M | – |
| FY2013 | Dec 31, 2013 | -$15.00M | – |
| FY2012 | Dec 31, 2012 | -$13.59M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$44.03M | – |
| Q1 FY2026 | Mar 31, 2026 | -$44.61M | – |
| Q2 FY2025 | Jun 30, 2025 | -$19.38M | – |
| Q1 FY2025 | Mar 31, 2025 | -$26.54M | – |
| Q4 FY2024 | Dec 31, 2024 | -$21.82M | – |
| Q3 FY2024 | Sep 30, 2024 | -$24.55M | – |
| Q2 FY2024 | Jun 30, 2024 | -$13.99M | – |
| Q1 FY2024 | Mar 31, 2024 | -$10.41M | – |
| Q4 FY2023 | Dec 31, 2023 | -$9.34M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.20M | – |
| Q2 FY2023 | Jun 30, 2023 | -$7.37M | – |
| Q1 FY2023 | Mar 31, 2023 | -$7.55M | – |
| Q4 FY2022 | Dec 31, 2022 | -$6.67M | – |
| Q3 FY2022 | Sep 30, 2022 | -$5.88M | – |
| Q2 FY2022 | Jun 30, 2022 | -$7.49M | – |
| Q1 FY2022 | Mar 31, 2022 | -$7.53M | – |
| Q4 FY2021 | Dec 31, 2021 | -$7.92M | – |
| Q3 FY2021 | Sep 30, 2021 | -$12.20M | – |
| Q2 FY2021 | Jun 30, 2021 | -$10.78M | – |
| Q1 FY2021 | Mar 31, 2021 | -$11.21M | – |
| Q4 FY2020 | Dec 31, 2020 | -$9.86M | – |
| Q3 FY2020 | Sep 30, 2020 | -$11.22M | – |
| Q2 FY2020 | Jun 30, 2020 | -$12.20M | -447.9% |
| Q1 FY2020 | Mar 31, 2020 | -$8.92M | – |
| Q4 FY2019 | Dec 31, 2019 | -$7.91M | – |
| Q3 FY2019 | Sep 30, 2019 | -$5.82M | – |
| Q2 FY2019 | Jun 30, 2019 | $3.51M | – |
| Q1 FY2019 | Mar 31, 2019 | -$12.47M | – |
| Q4 FY2018 | Dec 31, 2018 | -$11.83M | – |
| Q3 FY2018 | Sep 30, 2018 | -$13.08M | – |
| Q2 FY2018 | Jun 30, 2018 | -$13.31M | – |
| Q1 FY2018 | Mar 31, 2018 | -$13.27M | – |
| Q4 FY2017 | Dec 31, 2017 | -$9.84M | – |
| Q3 FY2017 | Sep 30, 2017 | -$12.09M | – |
| Q2 FY2017 | Jun 30, 2017 | -$10.18M | – |
| Q1 FY2017 | Mar 31, 2017 | -$11.68M | – |
| Q4 FY2016 | Dec 31, 2016 | -$8.67M | – |
| Q3 FY2016 | Sep 30, 2016 | -$11.03M | – |
See a number that looks wrong?